- Takeda acquires rights to IBI363 and IBI343 outside Greater China.
- IBI363 targets non-small cell lung and colorectal cancers; IBI343 targets gastric and pancreatic cancers.
- Takeda will pay Innovent $1.2 billion upfront, including a $100 million equity investment.
- The financial impact is included in Takeda's forecast for the fiscal year ending March 31, 2026.
Agreement Details
Takeda has finalized a license and collaboration agreement with Innovent Biologics, acquiring rights to two investigational oncology medicines, IBI363 and IBI343, outside of Greater China. The agreement was initially announced on October 21, 2025.
Medicine Focus
IBI363 is being evaluated for non-small cell lung and colorectal cancers, with potential efficacy in other solid tumors. IBI343 targets gastric and pancreatic cancers, addressing unmet needs in these areas.
Development and Commercialization
Takeda will lead global co-development and U.S. co-commercialization of IBI363, with exclusive commercialization rights outside the U.S. and Greater China. For IBI343, Takeda holds exclusive rights to develop, manufacture, and commercialize worldwide, excluding Greater China.
Financial Terms
Takeda will pay Innovent $1.2 billion upfront, including a $100 million equity investment. This financial impact is reflected in Takeda's revised forecast for the fiscal year ending March 31, 2026.
